Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports brain RAS as a research target in neurogenic hypertension; leaves open any clinical targeting.
The components of the Renin-Angiotensin System (RAS) have been found to be expressed in the brain. Angiotensinogen, the high molecular weight precursor of the system, is widely distributed and expressed in areas not related to control of blood pressure and body fluid homeostasis as well. It has been shown that it is regulated by steroid hormones independently from the liver and that it is also regulated in a different manner in several brain areas. Angiotensin II, the effector peptide of the system, may be generated in the brain via the classical pathway, using renin and angiotensin converting enzyme or directly from angiotensinogen by cathepsin G or tonin. N-terminal peptides of angiotensin II have been found in several brain areas with ANG (1-7) involved in vasopressin release however without influence on blood pressure and with ANG III acting as potent as ANG II. Transgenic animals may be used to study the pathophysiology of an activated brain RAS.
No takes yet. Share an insight, caveat, or question.
Lippoldt et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: